MX2020011588A - Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. - Google Patents
Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.Info
- Publication number
- MX2020011588A MX2020011588A MX2020011588A MX2020011588A MX2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A
- Authority
- MX
- Mexico
- Prior art keywords
- lag
- binding proteins
- high affinity
- affinity antibodies
- made therefrom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen anticuerpos de alta afinidad que reconocen el Ligando 1 de Muerte Programada (PD-1) y la proteína del Gen 3 de Activación Linfocitica (LAG-3). Los sitios de unión de los anticuerpos anti-PD-1 y anti-LAG-3 humanizados se incorporan en un formato de inmunoglobulina Fabs-en-Tandem sin pérdida significativa de afinidad de unión, y las proteínas de unión biespecíficas y multivalentes resultantes pueden unirse tanto a PD- 1 y LAG-3 simultáneamente. Tales proteínas de unión a FIT-Ig biespecíficas son útiles para el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018085468 | 2018-05-03 | ||
PCT/CN2019/085164 WO2019210848A1 (en) | 2018-05-03 | 2019-04-30 | High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011588A true MX2020011588A (es) | 2020-12-07 |
Family
ID=68386276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011588A MX2020011588A (es) | 2018-05-03 | 2019-04-30 | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US12060425B2 (es) |
EP (1) | EP3788079A4 (es) |
JP (1) | JP7368453B2 (es) |
KR (1) | KR20210005894A (es) |
CN (1) | CN112074541A (es) |
AU (1) | AU2019263850A1 (es) |
BR (1) | BR112020022371A2 (es) |
CA (1) | CA3097916A1 (es) |
MX (1) | MX2020011588A (es) |
TW (1) | TWI784190B (es) |
WO (1) | WO2019210848A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2769133C2 (ru) * | 2013-12-30 | 2022-03-28 | Эпимаб Биотерапьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
MX2022006230A (es) * | 2019-11-26 | 2022-06-22 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos. |
CN115819585B (zh) * | 2020-12-10 | 2023-06-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
WO2022166987A1 (zh) * | 2021-02-08 | 2022-08-11 | 迈威(上海)生物科技股份有限公司 | 结合lag-3的抗体及其用途 |
TW202300516A (zh) * | 2021-03-10 | 2023-01-01 | 大陸商北京拓界生物醫藥科技有限公司 | Pd—1結合蛋白及其醫藥用途 |
CR20230462A (es) * | 2021-03-31 | 2023-11-30 | Incyte Corp | Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 novedosos. |
CN114989297B (zh) * | 2022-06-14 | 2022-10-25 | 北京科跃中楷生物技术有限公司 | 包含辣根过氧化物酶标记的抗体的试剂盒 |
TW202421193A (zh) * | 2022-09-28 | 2024-06-01 | 美商英塞特公司 | 抗pd-1/lag-3雙特異性抗體及其用途 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK172110B1 (da) | 1988-04-15 | 1997-10-27 | Gen Hospital Corp | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner |
US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
WO2001077342A1 (en) | 2000-04-11 | 2001-10-18 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
EP1297172B1 (en) | 2000-06-28 | 2005-11-09 | Glycofi, Inc. | Methods for producing modified glycoproteins |
KR100923514B1 (ko) | 2000-12-28 | 2009-10-27 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
DK1648509T3 (da) | 2003-07-15 | 2013-01-07 | Amgen Inc | Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
JP2007528723A (ja) | 2003-08-22 | 2007-10-18 | メディミューン,インコーポレーテッド | 抗体のヒト化 |
US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
US20050250185A1 (en) | 2003-12-12 | 2005-11-10 | Murphy Andrew J | OGH fusion polypeptides and therapeutic uses thereof |
PL1730191T3 (pl) | 2004-03-30 | 2011-12-30 | Glaxo Group Ltd | Immunoglobuliny wiążące hosm |
CN1997382A (zh) | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
EP1863844A1 (en) | 2005-02-28 | 2007-12-12 | Centocor, Inc. | Heterodimeric protein binding compositions |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
EP1907424B1 (en) | 2005-07-01 | 2015-07-29 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
EP2484774A3 (en) | 2005-07-21 | 2012-11-14 | Abbott Laboratories | Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP3178850B1 (en) | 2005-10-11 | 2021-01-13 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
DK2481753T3 (en) | 2005-12-13 | 2018-06-18 | Lilly Co Eli | Anti-IL-17 antibodies |
AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
ES2618292T3 (es) | 2008-01-31 | 2017-06-21 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras |
CA2716851A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and egfr antagonists |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
RU2010153580A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двумя вариабельными доменами и их применение |
JP2011526591A (ja) | 2008-06-30 | 2011-10-13 | ノボ・ノルデイスク・エー/エス | 抗ヒトインターロイキン−20抗体 |
KR101431318B1 (ko) | 2009-04-02 | 2014-08-20 | 로슈 글리카트 아게 | 전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체 |
US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8802375B2 (en) | 2009-09-14 | 2014-08-12 | Icahn School Of Medicine At Mount Sinai | Methods for characterizing antibody binding affinity and epitope diversity in food allergy |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US9862769B2 (en) | 2010-05-27 | 2018-01-09 | Genmab A/S | Monoclonal antibodies against HER2 |
WO2012025525A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
SG10201604699VA (en) | 2010-12-21 | 2016-07-28 | Abbvie Inc | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
EP2654789B1 (en) | 2010-12-22 | 2018-05-30 | Orega Biotech | Antibodies against human cd39 and use thereof |
JP2014515598A (ja) | 2011-03-10 | 2014-07-03 | エイチシーオー アンティボディ, インク. | 二重特異性三鎖抗体様分子 |
JP5908972B2 (ja) | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
LT2748202T (lt) | 2011-08-23 | 2018-09-25 | Roche Glycart Ag | Bispecifinės antigeną surišančios molekulės |
JP6339015B2 (ja) | 2011-08-23 | 2018-06-06 | ロシュ グリクアート アーゲー | 二重特異性t細胞活性化抗原結合分子 |
NO2802607T3 (es) | 2012-01-13 | 2018-03-03 | ||
JP6007310B2 (ja) | 2012-04-05 | 2016-10-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ヒトtweak及びヒトil17に対する二重特異性抗体並びにその使用 |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
US20160009824A1 (en) | 2013-03-15 | 2016-01-14 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
WO2014166029A1 (zh) | 2013-04-07 | 2014-10-16 | 永卓博济(上海)生物医药技术有限公司 | 针对表皮生长因子受体的抗体 |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
BR112016011222A2 (pt) | 2013-12-12 | 2017-09-19 | Novartis Ag | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer |
RU2769133C2 (ru) * | 2013-12-30 | 2022-03-28 | Эпимаб Биотерапьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015134411A1 (en) | 2014-03-03 | 2015-09-11 | Academia Sinica | Bi-specific antibodies and uses thereof |
LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
EP3760229A3 (en) | 2014-05-15 | 2021-04-07 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
PL3608337T3 (pl) | 2014-08-04 | 2024-07-22 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujący limfocyty T |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
AR101875A1 (es) | 2014-09-15 | 2017-01-18 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas |
PT3212226T (pt) | 2014-10-31 | 2020-06-22 | Ngm Biopharmaceuticals Inc | Composições e métodos de utilização para tratamento de distúrbios metabólicos |
EP3215538A4 (en) | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
EP3747905A1 (en) | 2014-11-20 | 2020-12-09 | F. Hoffmann-La Roche AG | Common light chains and methods of use |
GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
PE20181151A1 (es) * | 2015-07-30 | 2018-07-17 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
WO2017087589A2 (en) * | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
JP2019509014A (ja) | 2015-11-23 | 2019-04-04 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Cd39血管アイソフォームターゲティング剤 |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
MX2018009581A (es) | 2016-02-06 | 2019-05-06 | Epimab Biotherapeutics Inc | Inmunoglobulina con fabs en tandem y sus usos. |
TW202408578A (zh) * | 2016-05-13 | 2024-03-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
SG11201811064TA (en) | 2016-06-20 | 2019-01-30 | F Star Delta Ltd | Binding molecules binding pd-l1 and lag-3 |
CN114456269A (zh) * | 2016-09-21 | 2022-05-10 | 基石药业(苏州)有限公司 | 一种新的pd-1单克隆抗体 |
KR20230136711A (ko) | 2016-10-13 | 2023-09-26 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항-lag-3 항체 및 조성물 |
EP3565833A1 (en) | 2017-01-09 | 2019-11-13 | Torch Therapeutics | Conditionally effective bispecific therapeutics |
US11345757B2 (en) | 2017-07-31 | 2022-05-31 | Trishula Therapeutics, Inc. | Anti-CD39 antibodies |
AU2018346447A1 (en) | 2017-10-06 | 2020-03-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
BR112020009655A8 (pt) | 2017-11-15 | 2023-03-21 | Innate Pharma | Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica |
CA3150168A1 (en) | 2019-08-08 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
-
2019
- 2019-04-30 AU AU2019263850A patent/AU2019263850A1/en active Pending
- 2019-04-30 US US17/051,834 patent/US12060425B2/en active Active
- 2019-04-30 WO PCT/CN2019/085164 patent/WO2019210848A1/en unknown
- 2019-04-30 CA CA3097916A patent/CA3097916A1/en active Pending
- 2019-04-30 CN CN201980030066.6A patent/CN112074541A/zh active Pending
- 2019-04-30 JP JP2021510507A patent/JP7368453B2/ja active Active
- 2019-04-30 BR BR112020022371-9A patent/BR112020022371A2/pt unknown
- 2019-04-30 EP EP19796462.0A patent/EP3788079A4/en active Pending
- 2019-04-30 KR KR1020207033251A patent/KR20210005894A/ko unknown
- 2019-04-30 MX MX2020011588A patent/MX2020011588A/es unknown
- 2019-08-12 TW TW108128587A patent/TWI784190B/zh active
Also Published As
Publication number | Publication date |
---|---|
US20210188980A1 (en) | 2021-06-24 |
EP3788079A1 (en) | 2021-03-10 |
CN112074541A (zh) | 2020-12-11 |
WO2019210848A1 (en) | 2019-11-07 |
EP3788079A4 (en) | 2022-12-21 |
TWI784190B (zh) | 2022-11-21 |
TW202041537A (zh) | 2020-11-16 |
JP7368453B2 (ja) | 2023-10-24 |
KR20210005894A (ko) | 2021-01-15 |
CA3097916A1 (en) | 2019-11-07 |
AU2019263850A1 (en) | 2020-11-19 |
BR112020022371A2 (pt) | 2021-02-02 |
JP2021522347A (ja) | 2021-08-30 |
US12060425B2 (en) | 2024-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011588A (es) | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. | |
MX2022006230A (es) | Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos. | |
MX2019012793A (es) | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. | |
MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
AU2018334886A1 (en) | Novel bispecific polypeptide complexes | |
EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
EP4039710A3 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
WO2016126858A3 (en) | Antibodies directed against lymphocyte activation gene 3 (lag-3) | |
MX2022014463A (es) | Construcciones de union a antigeno para moleculas diana. | |
MX2019010392A (es) | Moleculas de fusion de ectodominios receptores de tgf-b y sus usos. | |
PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
WO2019060750A3 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
EP4249511A3 (en) | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
WO2020123662A3 (en) | Fusion protein constructs for complement associated disease | |
WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
MX2023004054A (es) | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. | |
WO2020218951A3 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). | |
WO2022032003A3 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
MX2022003432A (es) | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. | |
MX2023013392A (es) | Anticuerpos para tratar alfa-sinucleinopatias. |